NEW YORK (GenomeWeb News) – Luminex reported after the close of the market a 10 percent rise in its third-quarter revenues, though the firm fell short of the consensus Wall Street estimate on the top line.

The Austin, Texas-based molecular diagnostics developer brought in total revenues of $50 million for the three months ended Sept. 30, up from $45.6 million for the third quarter of 2011. Analysts, on average, had expected revenues of $51.3 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Five researchers are to share this year's Albany Medical Center Prize for their work on the CRISPR/Cas9 gene-editing tool, the AP reports.

Stat News reports on how white supremacists cope with surprising genetic ancestry testing results.

In Genome Research this week: sex-biased gene expression evolution in malaria mosquitos, method to find ancient selective sweeps, and more.

Iceland has nearly eliminated Down syndrome from its population, CBS News reports.